Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology’s Most Critical Questions

Why It Matters

The analysis demonstrates that large‑scale real‑world evidence can pinpoint care disparities and inform both clinical decision‑making and drug development in a rapidly evolving oncology landscape.

Key Takeaways

• Panoramic datasets cover 420,000 GU cancer patient records globally
• Testing gaps persist beyond BRCA mutations in advanced prostate cancer
• Cisplatin‑ineligible bladder patients may still benefit from chemotherapy
• Post‑Lu177 therapeutic options remain limited for metastatic prostate cancer
• Real‑world evidence enables cross‑market analysis of treatment patterns

Pulse Analysis

The American Society of Genitourinary Cancers (ASCO GU) symposium has become a proving ground for data‑driven oncology, and Flatiron Health’s presence underscores that shift. Its Panoramic datasets integrate structured and unstructured electronic health record information across three continents, creating a unified model that allows researchers to compare outcomes, dosing trends, and survival metrics without geographic bias. This level of interoperability is rare, turning fragmented clinical notes into a cohesive evidence base that can accelerate hypothesis testing and regulatory submissions.

Within the symposium, Flatiron’s six accepted studies revealed persistent blind spots in current practice. One analysis showed that many men with advanced prostate cancer are missing comprehensive DNA‑repair testing, limiting access to PARP inhibitors beyond BRCA‑mutated cases. Another investigation suggested that even patients deemed ineligible for cisplatin due to comorbidities might still derive benefit from alternative chemotherapy regimens in muscle‑invasive bladder cancer. A third study highlighted a scarcity of effective therapies after Lu177‑PSMA treatment, signaling an urgent need for next‑generation agents. These findings collectively argue for broader biomarker testing, more inclusive trial designs, and a pipeline that anticipates post‑Lu177 disease trajectories.

For pharmaceutical firms, payers, and clinicians, the implications are clear: real‑world data can surface actionable gaps faster than traditional registries, guiding investment in targeted therapies and health‑policy reforms. Flatiron’s ability to aggregate and standardize data at scale positions it as a strategic partner for drug developers seeking to validate efficacy across diverse populations. As the oncology ecosystem moves toward precision medicine, the integration of such evidence will likely shape reimbursement models, clinical guidelines, and ultimately improve outcomes for patients facing genitourinary cancers.